Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kα pathway

Blood

Volumn 110, Issue 13, 2007, Pages 4243-4252

  Hers, Ingeborg ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; NVP AEW 541; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 1; SOMATOMEDIN C; 1 PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT, HUMAN; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, HUMAN; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; AUTOCRINE EFFECT; CELL CULTURE; CYTOLOGY; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; THROMBOCYTE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AUTOCRINE COMMUNICATION; BLOOD PLATELETS; CELLS, CULTURED; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PHOSPHORYLATION; PLATELET ACTIVATION; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 39649102180     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-050633     Document Type: Article

References (45)

1. Angelillo-Scherrer A, de Frutos P, Aparicio C, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med. 2001;7:215-221.
2. Balogh I, Hafizi S, Stenhoff J, Hansson K, Dahlback B. Analysis of Gas6 in human platelets and plasma. Arterioscler Thromb Vasc Biol. 2005;25:1280-1286.
3. Graham GJ, Stevens JM, Page NM, et al. Tachykinins regulate the function of platelets. Blood. 2004;104:1058-1065.
4. Karey KP, Sirbasku DA. Human platelet-derived mitogens, II: subcellular localization of insulin-like growth factor I to the alpha-granule and release in response to thrombin. Blood. 1989;74:1093-1100.
5. Chan K, Spencer EM. Megakaryocytes endocytose insulin-like growth factor (IGF) I and IGFbinding protein-3: a novel mechanism directing them into alpha granules of platelets. Endocrinology. 1998;139:559-565.
6. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:435-444.
7. Grazul-Bilska AT, Johnson ML, Bilski JJ, et al. Wound healing: the role of growth factors. Drugs Today (Barc). 2003;39:787-800.
8. Le Roith D. The insulin-like growth factor system. Exp Diabesity Res. 2003;4:205-212.
9. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101.
10. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114:2903-2910.
11. Vincent AM, Feldman EL. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res. 2002;12:193-197.
12. Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskov H. Cardiovascular disease and insulin-like growth factor I. Circulation. 2002;106:893-895.
13. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res. 2004;59:207-223.
14. Frystyk J. Free insulin-like growth factors: measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004;14:337-375.
15. Frystyk J. The growth hormone hypothesis: 2005 revision. Horm Metab Res. 2005;37:44-48.
16. Colao A, Pivonello R, Marzullo P, et al. Severe systemic complications of acromegaly. J Endocrinol Invest. 2005;28:65-77.
17. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939-944.
18. Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol. 2001;38:26-32.
19. Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab. 2005;90:5937-5941.
20. Janssen JA, Lamberts SW. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol. 2002;146:467-477.
21. Clauson PG, Brismar K, Hall K, Linnarsson R, Grill V. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest. 1998;58:353-360.
22. Saetrum Opgaard O, Wang PH. IGF-I is a matter of heart. Growth Horm IGF Res. 2005;15:89-94.
23. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs. 2002;1:273-288.
24. Hartmann K, Baier TG, Loibl R, Schmitt A, Schonberg D. Demonstration of type I insulin-like growth factor receptors on human platelets. J Recept Res. 1989;9:181-198.
25. Hers I, Bell CJ, Poole AW, et al. Reciprocal feedback regulation of insulin receptor and insulin receptor substrate tyrosine phosphorylation by phosphoinositide 3-kinase in primary adipocytes. Biochem J. 2002;368:875-884.
26. Kroner C, Eybrechts K, Akkerman JW. Dual regulation of platelet protein kinase B. J Biol Chem. 2000;275:27790-27798.
27. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem. 2004;279:4186-4195.
28. Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst. 2006;98:545-556.
29. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733-747.
30. Chaussade C, Rewcastle GW, Kendall JD, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007;404:449-458.
31. Motani AS, Anggard EE, Ferns GA. Recombinant insulin-like growth factor-1 modulates aggregation in human platelets via extracellular calcium. Life Sci. 1996;58:PL269-PL274.
32. Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem. 2004;279:3254-3264.
33. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie. 2005;87:99-109.
34. Hers I, Tavare JM. Mechanism of feedback regulation of insulin receptor substrate-1 phosphorylation in primary adipocytes. Biochem J. 2005;388:713-720.
35. Rakatzi I, Stosik M, Gromke T, Siddle K, Eckel J. Differential phosphorylation of IRS-1 and IRS-2 by insulin and IGF-I receptors. Arch Physiol Biochem. 2006;112:37-47.
36. Jackson SF, Schoenwaelder SM. Type I phosphoinositide 3-kinases: potential antithrombotic targets? Cell Mol Life Sci. 2006;63:1085-1090.
37. Senis YA, Atkinson BT, Pearce AC, et al. Role of the p110delta PI 3-kinase in integrin and ITAM receptor signalling in platelets. Platelets. 2005;16:191-202.
38. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005;11:507-514.
39. Pasquet JM, Gross BS, Gratacap MP, et al. Thrombopoietin potentiates collagen receptor signaling in platelets through a phosphatidylinositol 3-kinase-dependent pathway. Blood. 2000;95:3429-3434.
40. Duan C, Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol. 2005;142:44-52.
41. Booth BA, Boes M, Bar RS. IGFBP-3 proteolysis by plasmin, thrombin, serum: heparin binding, IGF binding, and structure of fragments. Am J Physiol. 1996;271:E465-E470.
42. Zheng B, Clarke JB, Busby WH, Duan C, Clemmons DR. Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin. Endocrinology. 1998;139:1708-1714.
43. Mitsui Y, Mochizuki S, Kodama T, et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006;66:9913-9920.
44. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541: a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5:231-239.
45. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer. 2006;13:S33-S43.